Novo Nordisk A/S (NYSE:NVO) fell to $136.90

Shares of Novo Nordisk A/S (NYSE:NVO – Get your free report ) were down in pre-market trading on Tuesday. The stock had previously closed at $136.90 but opened at $133.60. Shares of Novo Nordisk A/S last traded at $133.58 with a volume of 417,313 shares.

Analysts set new price targets

NVO has been the subject of a number of research reports. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday. Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Argus boosted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, 8 August. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $145.17.

See the latest Novo Nordisk A/S stock report

Novo Nordisk A/S trading rose 0.1%

The company has a fifty day moving average of $133.52 and a 200 day moving average of $133.19. The company has a current ratio of 0.94, a quick ratio of 0.75, and a debt-to-equity ratio of 0.46. The company has a market cap of $592.76 billion, a price-to-earnings ratio of 45.55, a PEG ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO – Get Free Report ) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.11 earnings per share for the current fiscal year.

Novo Nordisk A/S cuts dividends

The firm also recently announced a semiannual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.83%.

Institutional investors are investing in Novo Nordisk A/S

A number of large investors have recently made changes to their positions in NVO. First PREMIER Bank purchased a new position in shares of Novo Nordisk A/S in the first quarter worth $25,000. 1620 Investment Advisors Inc. purchased a new position in shares of Novo Nordisk A/S in the second quarter worth $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new stake in Novo Nordisk A/S in the 1st quarter valued at approximately $26,000. Finally, Orion Capital Management LLC purchased a new position in Novo Nordisk A/S in the first quarter valued at about $26,000. 11.54% of the shares are currently held by hedge funds and other institutional investors.

Novo Nordisk A/S company profile

(Get a free report)

Novo Nordisk A/S, together with its subsidiaries, is engaged in research and development, manufacturing and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and internationally. It operates in two segments, diabetes and obesity care and rare diseases.

Recommended articles

Get news and reviews for Novo Nordisk A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Nordisk A/S and related companies with MarketBeat.com’s FREE daily email newsletter.